Development of a novel multi-epitope subunit mRNA vaccine candidate to combat Acinetobacter baumannii
Abstract Acinetobacter baumannii, an opportunistic bacterium prevalent in various environment, is a significant cause of nosocomial infections in ICUs. As the causative agent of pneumonia, septicemia, and meningitis, A. baumannii typically exhibits multidrug resistance and is associated with poor pr...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-01-01
|
| Series: | Scientific Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1038/s41598-024-84823-0 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841544784459595776 |
|---|---|
| author | Shiyang Ma Fei Zhu Peipei Zhang Yizhong Xu Ziyou Zhou Hang Yang Caixia Tan Jie Chen Pinhua Pan |
| author_facet | Shiyang Ma Fei Zhu Peipei Zhang Yizhong Xu Ziyou Zhou Hang Yang Caixia Tan Jie Chen Pinhua Pan |
| author_sort | Shiyang Ma |
| collection | DOAJ |
| description | Abstract Acinetobacter baumannii, an opportunistic bacterium prevalent in various environment, is a significant cause of nosocomial infections in ICUs. As the causative agent of pneumonia, septicemia, and meningitis, A. baumannii typically exhibits multidrug resistance and is associated with poor prognosis, thus led to a challenge for researchers in developing new treatment and prevention methods. This study involved the development of a novel multi-epitope mRNA vaccine for A. baumannii and validation of in silico approaches was conducted. We screened 11 immunodominant epitopes for cytotoxic T cells, 5 for helper T cells, and 10 for Linear B-cell based on promising candidate proteins omp33-36, ompA and ompW, the selection of these three proteins is based on reverse vaccinology screening and previous work by other researchers. All predicted epitopes demonstrated strong antigenicity, immunogenicity without posing any potential harm to humans. Additionally, high conservancy is required to cover different strains. All epitopes, as well as adjuvants, were constructed into a final vaccine, which was further assessed by calculating its physicochemical properties. Next, we docked the vaccine protein with immune receptors and analyzed the complexes with dynamic simulations to evaluate its affinity to receptors. At last, the constructed sequence is translated to an mRNA sequence. The results indicated the constructed vaccine is capability of eliciting robust humoral and cellular immune responses, making it a promising candidate for protection against the targeted pathogen. |
| format | Article |
| id | doaj-art-ddc4d335fa9a4b19bbd2781885c11fa9 |
| institution | Kabale University |
| issn | 2045-2322 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj-art-ddc4d335fa9a4b19bbd2781885c11fa92025-01-12T12:17:39ZengNature PortfolioScientific Reports2045-23222025-01-0115111610.1038/s41598-024-84823-0Development of a novel multi-epitope subunit mRNA vaccine candidate to combat Acinetobacter baumanniiShiyang Ma0Fei Zhu1Peipei Zhang2Yizhong Xu3Ziyou Zhou4Hang Yang5Caixia Tan6Jie Chen7Pinhua Pan8Department of Respiratory Medicine, National Key Clinical Specialty, Branch of National Clinical Research Center for Respiratory Disease, Xiangya Hospital, Central South UniversityDepartment of Respiratory Medicine, National Key Clinical Specialty, Branch of National Clinical Research Center for Respiratory Disease, Xiangya Hospital, Central South UniversityDepartment of Respiratory Medicine, National Key Clinical Specialty, Branch of National Clinical Research Center for Respiratory Disease, Xiangya Hospital, Central South UniversityDepartment of Respiratory Medicine, National Key Clinical Specialty, Branch of National Clinical Research Center for Respiratory Disease, Xiangya Hospital, Central South UniversityDepartment of Respiratory Medicine, National Key Clinical Specialty, Branch of National Clinical Research Center for Respiratory Disease, Xiangya Hospital, Central South UniversityDepartment of Respiratory Medicine, National Key Clinical Specialty, Branch of National Clinical Research Center for Respiratory Disease, Xiangya Hospital, Central South UniversityDepartment of Infection Control Center of Xiangya Hospital, Central South UniversityDepartment of Respiratory Medicine, National Key Clinical Specialty, Branch of National Clinical Research Center for Respiratory Disease, Xiangya Hospital, Central South UniversityDepartment of Respiratory Medicine, National Key Clinical Specialty, Branch of National Clinical Research Center for Respiratory Disease, Xiangya Hospital, Central South UniversityAbstract Acinetobacter baumannii, an opportunistic bacterium prevalent in various environment, is a significant cause of nosocomial infections in ICUs. As the causative agent of pneumonia, septicemia, and meningitis, A. baumannii typically exhibits multidrug resistance and is associated with poor prognosis, thus led to a challenge for researchers in developing new treatment and prevention methods. This study involved the development of a novel multi-epitope mRNA vaccine for A. baumannii and validation of in silico approaches was conducted. We screened 11 immunodominant epitopes for cytotoxic T cells, 5 for helper T cells, and 10 for Linear B-cell based on promising candidate proteins omp33-36, ompA and ompW, the selection of these three proteins is based on reverse vaccinology screening and previous work by other researchers. All predicted epitopes demonstrated strong antigenicity, immunogenicity without posing any potential harm to humans. Additionally, high conservancy is required to cover different strains. All epitopes, as well as adjuvants, were constructed into a final vaccine, which was further assessed by calculating its physicochemical properties. Next, we docked the vaccine protein with immune receptors and analyzed the complexes with dynamic simulations to evaluate its affinity to receptors. At last, the constructed sequence is translated to an mRNA sequence. The results indicated the constructed vaccine is capability of eliciting robust humoral and cellular immune responses, making it a promising candidate for protection against the targeted pathogen.https://doi.org/10.1038/s41598-024-84823-0Acinetobacter baumanniiMultiepitope vaccineMolecular dockingMolecular dynamicsmRNA vaccine |
| spellingShingle | Shiyang Ma Fei Zhu Peipei Zhang Yizhong Xu Ziyou Zhou Hang Yang Caixia Tan Jie Chen Pinhua Pan Development of a novel multi-epitope subunit mRNA vaccine candidate to combat Acinetobacter baumannii Scientific Reports Acinetobacter baumannii Multiepitope vaccine Molecular docking Molecular dynamics mRNA vaccine |
| title | Development of a novel multi-epitope subunit mRNA vaccine candidate to combat Acinetobacter baumannii |
| title_full | Development of a novel multi-epitope subunit mRNA vaccine candidate to combat Acinetobacter baumannii |
| title_fullStr | Development of a novel multi-epitope subunit mRNA vaccine candidate to combat Acinetobacter baumannii |
| title_full_unstemmed | Development of a novel multi-epitope subunit mRNA vaccine candidate to combat Acinetobacter baumannii |
| title_short | Development of a novel multi-epitope subunit mRNA vaccine candidate to combat Acinetobacter baumannii |
| title_sort | development of a novel multi epitope subunit mrna vaccine candidate to combat acinetobacter baumannii |
| topic | Acinetobacter baumannii Multiepitope vaccine Molecular docking Molecular dynamics mRNA vaccine |
| url | https://doi.org/10.1038/s41598-024-84823-0 |
| work_keys_str_mv | AT shiyangma developmentofanovelmultiepitopesubunitmrnavaccinecandidatetocombatacinetobacterbaumannii AT feizhu developmentofanovelmultiepitopesubunitmrnavaccinecandidatetocombatacinetobacterbaumannii AT peipeizhang developmentofanovelmultiepitopesubunitmrnavaccinecandidatetocombatacinetobacterbaumannii AT yizhongxu developmentofanovelmultiepitopesubunitmrnavaccinecandidatetocombatacinetobacterbaumannii AT ziyouzhou developmentofanovelmultiepitopesubunitmrnavaccinecandidatetocombatacinetobacterbaumannii AT hangyang developmentofanovelmultiepitopesubunitmrnavaccinecandidatetocombatacinetobacterbaumannii AT caixiatan developmentofanovelmultiepitopesubunitmrnavaccinecandidatetocombatacinetobacterbaumannii AT jiechen developmentofanovelmultiepitopesubunitmrnavaccinecandidatetocombatacinetobacterbaumannii AT pinhuapan developmentofanovelmultiepitopesubunitmrnavaccinecandidatetocombatacinetobacterbaumannii |